간행물

생화학분자생물학회입니다.


BMB Reports

Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches

  • 작성자

    Eui-Cheol Shin, Hojun Choi
  • 작성일자

    2021-12-30
  • 조회수

    462
Name: Eui-Cheol Shin ( ecshin@kaist.ac.kr )
2007-present Assistant Professor, Associate Professor, and Professor, KAIST, Daejeon
2002-2007 Postdoctoral Fellow, NIDDK, NIH, Bethesda, Maryland, USA
1996-2001 Master & Ph.D. (in Microbiology/Immunology) Yonsei University, Seoul
1990-1996 M.D. Yonsei University College of Medicine, Seoul
Name: Hojun Choi ( hchoi@iliasbio.com )
2021-present Senior Researcher, ILIAS Biologics, Daejeon
2015-2021 Master & Ph.D. Department of Bio and Brain Engineering, KAIST, Daejeon
2011-2014 B.S. Department of Bio and Brain Engineering, KAIST, Daejeon

Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches

Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe COVID-19 exhibit hyper-inflammatory responses characterized by excessive activation of myeloid cells, including monocytes, macrophages, and neutrophils and a plethora of pro-inflammatory cytokines and chemokines. Accumulating evidence also indicates that hyper-inflammation is a driving factor for severe progression of the disease, which has prompted the development of anti-inflammatory therapies for the treatment of patients with COVID-19. Corticosteroids, IL-6R inhibitors, and JAK inhibitors have demonstrated promising results in treating patients with severe disease. In addition, diverse forms of exosomes that exert anti-inflammatory functions have been tested experimentally for the treatment of COVID-19. Here, we briefly describe the immunological mechanisms of the hyper-inflammatory responses in patients with severe COVID-19. We also summarize current anti-inflammatory therapies for the treatment of severe COVID-19 and novel exosome-based therapeutics that are in experimental stages.


BMB Rep. 2021 Dec 14;5488. [Online ahead of print]
https://pubmed.ncbi.nlm.nih.gov/34903319/